Future Medicine: Biomarkers in Medicine This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Association of < em > HLA-G < /em > 3' untranslated region indel polymorphism and its serum expression with susceptibility to colorectal cancer
Conclusion: These findings suggest that HLA-G could be a promising biomarker for CRC, and further research could lead to improved screening and treatment for more personalized care.PMID:37750737 | DOI:10.2217/bmm-2023-0212 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - September 26, 2023 Category: Internal Medicine Authors: Garrach Behaeddin Ben Othmen Abdelwaheb Khamlaoui Wided Yatouji Sonia Toumi Iheb Zaied Sonia Zouari Khadija Hammami Mohamed Hammami Sonia Source Type: research

US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers
Biomark Med. 2023 Sep 15. doi: 10.2217/bmm-2023-0351. Online ahead of print.ABSTRACTThe US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on commo...
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Abena S Agyeman Abbas Bandukwala Khaled Bouri Jessica Hawes Daniel M Krainak Samir Lababidi William B Mattes Elena V Mishina Phillip Turfle Sue-Jane Wang Theresa Thekkudan Source Type: research

CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.PMID:37713234 | DOI:10.2217/bmm-2023-0202 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Cuicui Li Litian Zhang Qiqi Jin Haoyun Jiang Chongyang Wu Source Type: research

US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers
Biomark Med. 2023 Sep 15. doi: 10.2217/bmm-2023-0351. Online ahead of print.ABSTRACTThe US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on commo...
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Abena S Agyeman Abbas Bandukwala Khaled Bouri Jessica Hawes Daniel M Krainak Samir Lababidi William B Mattes Elena V Mishina Phillip Turfle Sue-Jane Wang Theresa Thekkudan Source Type: research

CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.PMID:37713234 | DOI:10.2217/bmm-2023-0202 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Cuicui Li Litian Zhang Qiqi Jin Haoyun Jiang Chongyang Wu Source Type: research

US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers
Biomark Med. 2023 Sep 15. doi: 10.2217/bmm-2023-0351. Online ahead of print.ABSTRACTThe US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on commo...
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Abena S Agyeman Abbas Bandukwala Khaled Bouri Jessica Hawes Daniel M Krainak Samir Lababidi William B Mattes Elena V Mishina Phillip Turfle Sue-Jane Wang Theresa Thekkudan Source Type: research

CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.PMID:37713234 | DOI:10.2217/bmm-2023-0202 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Cuicui Li Litian Zhang Qiqi Jin Haoyun Jiang Chongyang Wu Source Type: research

US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers
Biomark Med. 2023 Sep 15. doi: 10.2217/bmm-2023-0351. Online ahead of print.ABSTRACTThe US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on commo...
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Abena S Agyeman Abbas Bandukwala Khaled Bouri Jessica Hawes Daniel M Krainak Samir Lababidi William B Mattes Elena V Mishina Phillip Turfle Sue-Jane Wang Theresa Thekkudan Source Type: research

CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.PMID:37713234 | DOI:10.2217/bmm-2023-0202 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - September 15, 2023 Category: Internal Medicine Authors: Cuicui Li Litian Zhang Qiqi Jin Haoyun Jiang Chongyang Wu Source Type: research